SuspendedPhase 1

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Stopped: Notice from Benefactor to stop Tazverik treatment. Participants can continue with standard of care treatment on study.

United States24 participantsStarted 2025-09-12

Plain-language summary

The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓-Note: For MZL, isolated splenomegaly and involvement of any biopsy proven extranodal site is considered measurable for this study. For MCL, clonal lymphocyte measured by flow cytometry is considered measurable. For WM, serum IgM level \>0.5 g/dL is considered measurable.

What they're measuring

Maximum Tolerated Dose (MTD) of tazemetostat in combination with zanubrutinib and anti-CD20 mAb

Timeframe: 2 years

Trial details

NCT IDNCT06824701

SponsorUniversity of Utah

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2032-01

View on ClinicalTrials.gov More Relapsed or Refractory B-cell Non-Hodgkin Lymphoma trials